NASDAQ:SVRA

Savara Stock Forecast, Price & News

$1.70

-0.10 (-5.56 %)

(As of 02/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.70

Now: $1.70▼

$1.90

50-Day Range

$1.31

MA: $1.67▼

$2.06

52-Week Range

$1.00

Now: $1.70▼

$3.17

Volume453,121 shs

Average Volume618,991 shs

Market Capitalization$92.04 million

P/E RatioN/A

Dividend YieldN/A

Beta1.18

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Headlines

Lumos Pharma Announces Changes to its Board of Directors - StreetInsider.com
February 16, 2021 | streetinsider.com

Is the Options Market Predicting a Spike in Savara (SVRA) Stock? - Yahoo Finance
February 5, 2021 | finance.yahoo.com

Is the Options Market Predicting a Spike in Savara (SVRA) Stock? - Nasdaq
February 5, 2021 | nasdaq.com

Is the Options Market Predicting a Spike in Savara (SVRA) Stock?
February 5, 2021 | finance.yahoo.com

Is Savara (NASDAQ:SVRA) Using Too Much Debt?
January 21, 2021 | finance.yahoo.com

Red tape, confusion block COVID homeless aid from cash-strapped cities, counties across US - USA TODAY
December 29, 2020 | usatoday.com

Foundation Fighting Blindness Appoints Peter Ginsberg as Executive Vice President, Corporate Development, Chief Business Officer - StreetInsider.com
December 10, 2020 | streetinsider.com

Is SVRA A Good Stock To Buy Now? - Yahoo Finance
December 10, 2020 | finance.yahoo.com

Is SVRA A Good Stock To Buy Now?
December 10, 2020 | finance.yahoo.com

Savara Provides Pipeline and Business Update - Business Wire
December 10, 2020 | businesswire.com

Savara Provides Pipeline and Business Update
December 10, 2020 | finance.yahoo.com

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences
November 24, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SVRA

Previous SymbolAMEX:ANX

CUSIPN/A

CIK1160308

Webwww.savarapharma.com

Phone512-614-1848

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.33

Current Ratio12.61

Quick Ratio12.61

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash Flow$6.54 per share

Price / Cash Flow0.26

Book Value$2.47 per share

Price / Book0.69

Profitability

EPS (Most Recent Fiscal Year)$4.57

Net Income$-78,170,000.00

Net MarginsN/A

Return on Equity-55.13%

Return on Assets-40.08%

Miscellaneous

Outstanding Shares54,141,000

Market Cap$92.04 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.93 out of 5 stars

Medical Sector

84th out of 1,960 stocks

Pharmaceutical Preparations Industry

31st out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
Savara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Savara has a forecasted upside of 76.5% from its current price of $1.70.
Amount of Analyst Coverage
Savara has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Savara has received 265 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Savara has received 285 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Savara has received 51.82% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote “Outperform” if you believe SVRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Savara does not currently pay a dividend.
Dividend Growth
Savara does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Savara insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,938.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.77% of the stock of Savara is held by insiders.
Percentage Held by Institutions
40.66% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Savara are expected to grow in the coming year, from ($0.71) to ($0.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Savara is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Savara is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Savara has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$1.70

-0.10 (-5.56 %)

(As of 02/26/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Savara (NASDAQ:SVRA) Frequently Asked Questions

Is Savara a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara or view top-rated stocks.

What stocks does MarketBeat like better than Savara?

Wall Street analysts have given Savara a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Savara wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Savara.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The company had revenue of $0.26 million for the quarter.
View Savara's earnings history.

How has Savara's stock price been impacted by Coronavirus?

Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SVRA stock has decreased by 28.0% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for SVRA?

2 analysts have issued 1 year price targets for Savara's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Savara's stock price to reach $3.00 in the next year. This suggests a possible upside of 76.5% from the stock's current price.
View analysts' price targets for Savara or view top-rated stocks among Wall Street analysts.

Who are Savara's key executives?

Savara's management team includes the following people:

Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
David L. Lowrance, Chief Financial Officer (Age 50)
Nevan C. Elam, Independent Director (Age 49)
Richard J. Hawkins, Independent Director (Age 68)
Joseph S. McCracken Ph.D., Independent Director (Age 64)
Matthew Pauls J.D., Independent Director (Age 46)
Yuri Pikover, Independent Director (Age 56)

Who are some of Savara's key competitors?

Some companies that are related to Savara include Forte Biosciences (FBRX), CytomX Therapeutics (CTMX), Nabriva Therapeutics (NBRV), ANI Pharmaceuticals (ANIP), Oncorus (ONCR), Aeglea BioTherapeutics (AGLE), Verrica Pharmaceuticals (VRCA), Sesen Bio (SESN), VistaGen Therapeutics (VTGN), Fortress Biotech (FBIO), Paratek Pharmaceuticals (PRTK), Trevena (TRVN), CymaBay Therapeutics (CBAY), Immunic (IMUX) and Nature's Sunshine Products (NATR).
View all of SVRA's competitors.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.56%), Northern Trust Corp (0.93%), Renaissance Technologies LLC (0.74%), JPMorgan Chase & Co. (0.27%), Brown Advisory Inc. (0.21%) and Dimensional Fund Advisors LP (0.20%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Matthew Pauls and Richard J Hawkins.
View institutional ownership trends for Savara.

Which major investors are selling Savara stock?

SVRA stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Dimensional Fund Advisors LP, and Northern Trust Corp.
View insider buying and selling activity for Savara or view top insider-selling stocks.

Which major investors are buying Savara stock?

SVRA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Brown Advisory Inc., Renaissance Technologies LLC, and Rhumbline Advisers. Company insiders that have bought Savara stock in the last two years include David A Ramsay, and Matthew Pauls.
View insider buying and selling activity for Savara or or view top insider-buying stocks.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.70.

How much money does Savara make?

Savara has a market capitalization of $92.04 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

Where are Savara's headquarters?

Savara is headquartered at 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here